AB-101
Sponsors
Artiva Biotherapeutics Inc., Applied Biology, Inc., Artiva Biotherapeutics, Inc., Affimed GmbH, Arbutus Biopharma Corporation
Conditions
Breast CancerCancer of BreastChronic Hepatitis bGranulomatosis With PolyangiitisIdiopathic Inflammatory Myopathies (IIMs)Lupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVNeuropathy
Early Phase 1
Phase 1
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
CompletedNCT04673617
Start: 2021-03-29End: 2025-10-06Updated: 2026-04-03
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
CompletedNCT05960240
Start: 2023-08-30End: 2026-02-09Updated: 2026-04-13
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
Active, not recruitingNCT06265220
Start: 2024-04-03End: 2027-08-31Target: 51Updated: 2025-12-10
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
RecruitingNCT06581562
Start: 2024-05-15End: 2028-12-31Target: 30Updated: 2024-09-03
Phase 2
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
TerminatedNCT05883449
Start: 2023-10-10End: 2025-06-13Updated: 2025-08-20
An open-label Phase 2a study to evaluate the safety and efficacy of AlloNK®, an allogeneic cord blood-derived NK cell therapy, in combination with rituximab in relapsing forms of B-cell dependent rheumatologic diseases
Not yet recruitingCTIS2025-520461-41-00
Target: 40Updated: 2026-01-26